MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
February 21 2022 - 9:05AM
MannKind Corporation (Nasdaq: MNKD) will release
its 2021 fourth quarter and full year financial results, and its
management will host a conference call to discuss the financial
results and corporate updates at 5:00 p.m. (Eastern Time) on
Thursday, February 24, 2022.
Presenting from the Company will be its Chief
Executive Officer Michael Castagna and Chief Financial Officer
Steven Binder.
Those interested in listening to the conference call live via
the internet may do so by visiting the Investors page of the
Company’s website at mannkindcorp.com under Events &
Presentations.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located in Danbury,
Conn., and Westlake Village, Calif. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
For MannKind:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024